🔥 Ranking
--------
K-POP

ENHYPEN Adds Berlin and London Shows as 'BLOOD SAGA' Expands to 37 Dates

Hannah Gonzalez [email protected]Sep 7, 2026, 7:43 PM EDT
Share
ENHYPEN "THE SIN : BLISS" Main Visualizer Image / BELIFT LAB (HYBE)
ENHYPEN "THE SIN : BLISS" Main Visualizer Image / BELIFT LAB (HYBE)

ENHYPEN is adding shows onto their ongoing BLOOD SAGA World Tour, with new dates in both Berlin and London, this now turns this tour into their largest one to date with 37 performances across 22 cities.

The group announced the additional dates through its official Weverse community on September 8.

ENHYPEN will now perform an additional show in Berlin on March 6, followed by another in London on March 8, expanding the European leg of ENHYPEN WORLD TOUR 'BLOOD SAGA'.

ENHYPEN 'BLOOD SAGA Berlin Poster' / BELIFT LAB (HYBE)
ENHYPEN 'BLOOD SAGA Berlin Poster' / BELIFT LAB (HYBE)

The tour began in Seoul in May, with both the opening concerts and the group's August shows in Busan selling out during fan presales. ENHYPEN's North and South American leg drew approximately 193,000 concertgoers and also marked the group's first performances in Latin America.

In São Paulo, ENHYPEN sold out a stadium show with a capacity of approximately 41,000, while demand in Mexico City led the group to expand an initially scheduled single concert to three shows.

Now, with the new show additions, BLOOD SAGA has grown to a total of 37 concerts across 22 cities worldwide, setting a new record as the largest world tour of ENHYPEN's career.

ENHYPEN 'BLOOD SAGA London Poster' / BELIFT LAB (HYBE)
ENHYPEN 'BLOOD SAGA London Poster' / BELIFT LAB (HYBE)

Outside of touring, ENHYPEN recently concluded official promotions for its eighth mini album THE SIN : BLISS. Title track "Bloody Paradise" earned six music show wins, the highest total for a single song in the group's career, as well as its first music show grand slam.

The group will return to Show Champion on September 9 for a special performance following the end of promotions.

Add K-POPIT as a preferred source on Google

Comments (0)

Loading comments…